R Squared’s PDS Biotechnology PDSB Stock Holding History

R Squared’s Portfolio PDSB Stock Details PDSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-300	Closed	-$489	–	1151
2024 Q4	$489	Buy	+300	New	+$794	﹤0.01%	1539

Other funds holding PDSB

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return

R Squared's PDSB Position: Q1 2025 in Review

R Squared sold out of PDS Biotechnology (PDSB) in Q1 2025, closing a stake of 300 shares — an estimated $489 sold.

R Squared first reported a position in PDSB in Q4 2024 and held it in 1 quarter. The position peaked at $489 in Q4 2024. 48 funds tracked by Wall St. Rank hold PDSB as of Q1 2025.

R Squared reported no remaining PDS Biotechnology position as of Q1 2025 after selling out during the quarter.
R Squared sold 300 PDS Biotechnology shares in Q1 2025, an estimated $489.
R Squared first reported a position in PDS Biotechnology in Q4 2024 and held it in 1 quarter.
R Squared's PDS Biotechnology position peaked at $489 in Q4 2024.
48 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.